# Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma

- Source: PR Newswire M&A
- Published: 2026-11-17T21:53:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/inhibrx-announces-updated-clinical-data-for-ozekibart-inbrx-109-in-ewing-sarcoma-302942893.html
- Canonical: https://groundlevelnews.com/story/inhibrx-announces-updated-clinical-data-for-ozekibart-inbrx-109-in-ewi-b2c912/

- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR; - 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
